MX2021008546A - Terapia combinada con un profarmaco de 6-diazo-5-oxo-l-norleucina (don) y un inhibidor de puntos de control inmunologicos. - Google Patents
Terapia combinada con un profarmaco de 6-diazo-5-oxo-l-norleucina (don) y un inhibidor de puntos de control inmunologicos.Info
- Publication number
- MX2021008546A MX2021008546A MX2021008546A MX2021008546A MX2021008546A MX 2021008546 A MX2021008546 A MX 2021008546A MX 2021008546 A MX2021008546 A MX 2021008546A MX 2021008546 A MX2021008546 A MX 2021008546A MX 2021008546 A MX2021008546 A MX 2021008546A
- Authority
- MX
- Mexico
- Prior art keywords
- diazo
- acetamido
- oxohexanoate
- propanamido
- indol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794231P | 2019-01-18 | 2019-01-18 | |
| PCT/US2020/014149 WO2020150639A1 (en) | 2019-01-18 | 2020-01-17 | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008546A true MX2021008546A (es) | 2021-11-12 |
Family
ID=71614516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008546A MX2021008546A (es) | 2019-01-18 | 2020-01-17 | Terapia combinada con un profarmaco de 6-diazo-5-oxo-l-norleucina (don) y un inhibidor de puntos de control inmunologicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220117938A1 (https=) |
| EP (1) | EP3911310A4 (https=) |
| JP (1) | JP7574198B2 (https=) |
| KR (1) | KR20210117303A (https=) |
| CN (1) | CN113438947A (https=) |
| AU (1) | AU2020208637A1 (https=) |
| BR (1) | BR112021014112A2 (https=) |
| CA (1) | CA3126822A1 (https=) |
| EA (1) | EA202191992A1 (https=) |
| IL (1) | IL284907A (https=) |
| MX (1) | MX2021008546A (https=) |
| SG (1) | SG11202107317WA (https=) |
| WO (1) | WO2020150639A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220332676A1 (en) * | 2019-10-03 | 2022-10-20 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof |
| WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| WO2022072820A1 (en) * | 2020-10-02 | 2022-04-07 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
| AU2021361970A1 (en) | 2020-10-15 | 2023-06-15 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| CN114621120B (zh) * | 2020-12-10 | 2023-11-03 | 深圳先进技术研究院 | 一种don前药分子、前药激活化合物和前药激活体系 |
| US20240246902A1 (en) * | 2021-04-29 | 2024-07-25 | The Johns Hopkins University | Prodrugs of 6-diazo-5-oxo-l-norleucine |
| WO2022261117A1 (en) * | 2021-06-07 | 2022-12-15 | Dracen Pharmaceuticals, Inc. | Combination therapy with a don prodrug and a tigit inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2015036499A1 (en) | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
| AU2015225867B2 (en) | 2014-03-07 | 2020-02-06 | University Health Network | Methods and compositions for modifying the immune response |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| EA034571B1 (ru) | 2015-07-31 | 2020-02-21 | Дзе Джонс Хопкинс Юниверсити | Пролекарства аналогов глутамина |
| CN108135872A (zh) | 2015-07-31 | 2018-06-08 | 约翰霍普金斯大学 | 用于治疗认知缺陷的谷氨酰胺拮抗剂 |
| CN108135875B (zh) | 2015-07-31 | 2021-12-31 | 约翰霍普金斯大学 | 用于治疗代谢重编程病症的方法和组合物 |
| WO2017040666A2 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| EP3612839A1 (en) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy |
| EP3692015B1 (en) * | 2017-10-06 | 2022-08-24 | The John Hopkins University | Novel glutamine antagonists and uses thereof |
-
2020
- 2020-01-17 JP JP2021541578A patent/JP7574198B2/ja active Active
- 2020-01-17 EP EP20741361.8A patent/EP3911310A4/en not_active Withdrawn
- 2020-01-17 BR BR112021014112-0A patent/BR112021014112A2/pt not_active IP Right Cessation
- 2020-01-17 CA CA3126822A patent/CA3126822A1/en active Pending
- 2020-01-17 SG SG11202107317WA patent/SG11202107317WA/en unknown
- 2020-01-17 WO PCT/US2020/014149 patent/WO2020150639A1/en not_active Ceased
- 2020-01-17 US US17/423,819 patent/US20220117938A1/en not_active Abandoned
- 2020-01-17 EA EA202191992A patent/EA202191992A1/ru unknown
- 2020-01-17 AU AU2020208637A patent/AU2020208637A1/en not_active Abandoned
- 2020-01-17 CN CN202080013742.1A patent/CN113438947A/zh active Pending
- 2020-01-17 KR KR1020217026015A patent/KR20210117303A/ko not_active Ceased
- 2020-01-17 MX MX2021008546A patent/MX2021008546A/es unknown
-
2021
- 2021-07-18 IL IL284907A patent/IL284907A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020150639A1 (en) | 2020-07-23 |
| US20220117938A1 (en) | 2022-04-21 |
| EP3911310A4 (en) | 2022-10-12 |
| IL284907A (en) | 2021-09-30 |
| SG11202107317WA (en) | 2021-08-30 |
| EA202191992A1 (ru) | 2021-12-17 |
| CA3126822A1 (en) | 2020-07-23 |
| KR20210117303A (ko) | 2021-09-28 |
| CN113438947A (zh) | 2021-09-24 |
| JP2022518232A (ja) | 2022-03-14 |
| AU2020208637A1 (en) | 2021-09-09 |
| EP3911310A1 (en) | 2021-11-24 |
| BR112021014112A2 (pt) | 2021-10-13 |
| JP7574198B2 (ja) | 2024-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008546A (es) | Terapia combinada con un profarmaco de 6-diazo-5-oxo-l-norleucina (don) y un inhibidor de puntos de control inmunologicos. | |
| ZA201906269B (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| MX2022010270A (es) | Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion. | |
| MX2024004439A (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| BR112014012737A8 (pt) | sistema de planejamento de tratamento para gerar tratamento específico por paciente, sistema de terapia de radiação, método para gerar tratamento específico por paciente, e sistema de terapia de radiação | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| BR112018013731A2 (pt) | combinações anti-egfr para o tratamento de tumores | |
| MX2017001154A (es) | Metodos y combinaciones terapeuticas para tratar tumores. | |
| EA201892510A2 (ru) | Комбинированная терапия для лечения рака | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| BR112017009584A2 (pt) | tratamento de retinite pigmentosa com n-acetilcisteína amida | |
| BR112018008882A2 (pt) | método para tratar um distúrbio proliferativo e produto farmacêutico | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX388890B (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2017002364A (es) | Terapia de combinacion para tratamiento de cancer. | |
| MA39942A (fr) | Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2 | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| EA201591902A1 (ru) | Способы и композиции, использующие 4-амино-2-(2,6-диоксо-пиперидин-3-ил)изоиндолин-1,3-дион для лечения и контроля злокачественных опухолей центральной нервной системы | |
| EP4342544A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. |